Aptevo Therapeutics Inc. (APVO)
- Previous Close
0.7200 - Open
0.7110 - Bid 0.6692 x 100
- Ask 0.7459 x 100
- Day's Range
0.6701 - 0.7200 - 52 Week Range
0.6700 - 91.9600 - Volume
162,847 - Avg. Volume
261,330 - Market Cap (intraday)
1.141M - Beta (5Y Monthly) 4.93
- PE Ratio (TTM)
-- - EPS (TTM)
-67.0700 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.25
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
www.aptevotherapeutics.comRecent News: APVO
Performance Overview: APVO
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APVO
Valuation Measures
Market Cap
1.13M
Enterprise Value
-10.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.09
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.37
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-61.12%
Return on Equity (ttm)
-123.53%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-18.65M
Diluted EPS (ttm)
-67.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
16.9M
Total Debt/Equity (mrq)
49.74%
Levered Free Cash Flow (ttm)
-12.38M